Clear Search

Showing 6 results for “Manzi S” published 2022.

December 2022

A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus

Arthritis Rheumatol. 2022. Epub ahead of print doi: 10.1002/art.42392

Long-term extension study shows an acceptable long-term safety profile of anifrolumab in SLE, in addition to sustained improvements in disease activity and reduction in glucocorticoid use.

more…

September 2022
June 2022

Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials

Ann Rheum Dis 2022;81:962–969 doi: 10.1136/annrheumdis-2021-221847

Bruce, et al. investigate the degree of concordance between BICLA and SRI-4 response across anifrolumab trials (TULIP-1, TULIP-2 and MUSE) in order to better understand drivers of discrepant systemic lupus erythematosus (SLE) trial results.

more…

May 2022

Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials

Ann Rheum Dis. 2022; 0:1–11. doi: 10.1136/annrheumdis-2021-221425

IFN-I signalling plays a key role in SLE pathogenesis, and anifrolumab has demonstrated inhibitory effects on IFN-I signalling in patients with SLE. Vital, et al. characterised efficacy and safety of anifrolumab in patients with moderate-to-severe SLE based on interferon gene signature, demographic and clinical subgroups using data pooled from the Phase III TULIP-1 and -2 trials.

more…

February 2022

Evaluating the Construct of Damage in Systemic Lupus Erythematosus

Arthritis Care Res (Hoboken). 2021 Dec 28. Epub ahead of print

Study identifies shifts in the paradigm of systemic lupus erythematosus (SLE) damage and develops a unifying conceptual framework to inform development of a revised SLE Damage Index (SDI).

Shifts in the concept of damage in SLE have occurred with new insights into disease manifestations, diagnostics, and therapy. Consequently, there is a need for a revised SDI, to incorporate additional factors that contribute to damage accrual.

more…

Flares after Hydroxychloroquine Reduction or Discontinuation: Results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort

Ann Rheum Dis. 2021:annrheumdis-2021-221295. Epub ahead of print

Evidence suggests that hydroxychloroquine (HCQ) reduction/withdrawal may be safe in some stable patients, but in other settings it may be associated with disease flare. Almeida-Brasil, et al. sought to evaluate SLE flares following HCQ reduction or discontinuation versus HCQ maintenance. Their data suggest that maintaining HCQ was associated with a lower flare risk than reduction or discontinuation, even in patients with low disease activity or remission.

more…